Biomarker discovery has driven major advances in healthcare, but most traditional approaches rely on animal-produced antibodies. Researchers generate these antibodies by introducing human recombinant proteins into animals and harvesting the resulting antibodies. Maintaining commercial supply often requires continuous animal use.

Our Aptamarker platform eliminates the need for animals in biomarker discovery. It uses chemically synthesized DNA oligonucleotides applied directly to human biological samples.

Unlike traditional methods that train probes against single recombinant proteins, Aptamarker applies a deep library of 268 million probes to each sample. This allows direct interaction with proteins in their natural context, revealing structural and functional states as they exist in vivo. This is crucial because many diseases arise not from isolated proteins but from changes in protein function and interactions within biological systems.

Aptamarker is the only platform capable of characterizing these functional protein changes in any protein, from any species, offering a true paradigm shift in biomarker discovery.